Ahn-Gook Pharmaceutical Co., Ltd.
Financials
Valuation Metrics
Ahn-Gook Pharmaceutical Co., Ltd.'s Market Cap is ₩1324B. At end of 2025 it was ₩1103B. Ranked #1095 of 2,421 in KR market (top 45%), #568 of 1,640 on KOSDAQ (top 35%), #125 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 132.38B KRW | KR#1,095/2,421 Sec#125/231 |
| Revenue | 345.08B KRW | KR#777/2,421 Sec#36/231 |
| Net Income | 21.71B KRW | KR#673/2,421 Sec#46/231 |
| Total Assets | 310.95B KRW | KR#1,014/2,421 Sec#66/231 |
| Net Assets | 166.29B KRW | KR#1,068/2,421 Sec#75/231 |
| Employees | 420 | KR#581/2,421 Sec#47/231 |
| Value | ||
| P/E | 6.10x | KR#466/2,421 Sec#20/231 |
| P/B | 0.80x | KR#1,259/2,421 Sec#77/231 |
| P/S | 0.38x | KR#738/2,421 Sec#24/231 |
| EV/EBITDA | 7.01x | KR#382/2,421 Sec#12/231 |
| FCF Yield | 28.11% | KR#206/2,421 Sec#4/231 |
| Profitability | ||
| ROE | 13.06% | KR#411/2,421 Sec#28/231 |
| ROA | 6.98% | KR#517/2,421 Sec#41/231 |
| Op. Margin | 6.86% | KR#742/2,421 Sec#60/231 |
| Revenue Growth | 18.68% | KR#589/2,421 Sec#55/231 |
| Financial Health | ||
| Debt Ratio | 86.99% | KR#1,432/2,421 Sec#166/231 |
| Total Debt | 72.48B KRW | KR#849/2,421 Sec#58/231 |
| FCF | 37.22B KRW | KR#355/2,421 Sec#20/231 |
| Cash | 38.95B KRW | KR#868/2,421 Sec#56/231 |
| Current Ratio | 1.69x | KR#1,047/2,421 Sec#118/231 |
| Net Debt/EBITDA | 1.42x | KR#780/2,421 Sec#53/231 |
| Dividend | ||
| Div. Yield | 6.15% | KR#173/2,421 Sec#2/231 |
| Div. Growth | 43.86% | KR#274/2,421 Sec#13/231 |
| Performance | ||
| 1Y Return | 25.93% | KR#385/2,421 Sec#25/231 |
| 1M Return | -7.64% | KR#1,979/2,421 Sec#162/231 |
| From 52W High | -25.64% | KR#397/2,421 Sec#24/231 |
| 1Y MDD | -23.77% | KR#118/2,421 Sec#10/231 |
| Trading | ||
| Volume | 14,361 shares | KR#1,760/2,421 Sec#174/231 |
| Trading Value | 146.7M KRW | KR#1,387/2,421 Sec#142/231 |
| Foreign Own. | 4.38% | KR#968/2,421 Sec#86/231 |
| Per Share | ||
| EPS | 1,665 KRW | KR#507/2,421 Sec#34/231 |
| BPS | 12,750 KRW | KR#809/2,421 Sec#54/231 |
Company Info
Anguk Pharmaceutical, established in 1959, manufactures and sells pharmaceuticals and health functional foods, having been listed on the KOSDAQ market in 2000. It holds several competitive drugs, including Cinechura, Revotension, Revosartan, and Fevarojet, specializing in antitussive expectorant and circulatory system medications. Its Hanam-eup, Hwaseong-si plant, certified by GMP, ensures the production of high-quality pharmaceuticals and engages in contract manufacturing organization (CMO) to maintain stable supply. Anguk Pharmaceutical is headquartered in Gwacheon-si, Gyeonggi-do.